According to The Stock Sniper (@Ultra_Calls), Psyence BioMed (PBM) has regained full compliance with Nasdaq's continued listing standards following decisive corporate actions, as reported by newsfilecorp.com. Dr. Neil Maresky, CEO of Psyence BioMed, highlighted the company's debt-free balance sheet and strong cash position. For traders, this improved financial stability may increase institutional interest in PBM shares and could lead to higher trading volumes. In the broader context, a strengthened biotech sector could attract speculative capital away from riskier crypto assets in the short term, leading to potential shifts in liquidity across both markets (source: newsfilecorp.com/release/255780, @Ultra_Calls).